SCHEMBL265188

SCHEMBL265188

[O-][N+]1=Cc2ccccc2CC1

nearest known ligand 0.59

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.59
BCHE P06276 1/20 0.47
ACHE P22303 1/20 0.47
IP6K1 Q92551 2/20 0.38
TSHR P16473 1/20 0.33
KDM1A O60341 1/20 0.32
GPR84 Q9NQS5 1/20 0.30
HTR2C P28335 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31337867 1.00 MAOB (0.59) MAOBBCHEACHEIP6K1TSHR
SCHEMBL4429852 0.77 MAOB (0.42) MAOBBCHEACHETSHR
SCHEMBL31231150 0.74 MAOB (1.00) MAOBBCHEACHEIP6K1TSHR
SCHEMBL30311 0.74 MAOB (1.00) MAOBBCHEACHEIP6K1TSHR
SCHEMBL8530667 0.72 MAOB (0.96) MAOBBCHEACHEIP6K1TSHR
Bromide SCHEMBL1821620 0.72 MAOB (0.96) MAOBBCHEACHEIP6K1TSHR
SCHEMBL19042548 0.72 MAOB (0.57) MAOBBCHEACHEIP6K1TSHR
SCHEMBL1826027 0.71 ACHE (0.72) MAOBBCHEACHEIP6K1
SCHEMBL19042688 0.69 MAOB (0.53) MAOBBCHEACHEIP6K1TSHR
SCHEMBL14493815 0.69 MAOB (0.58) MAOBBCHEACHEIP6K1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12247300-B2 Cleaning solution and cleaning method FUJIFILM CORPORATION (JP) 2025-03-11 US disclosed
US-12012467-B2 Small molecule DCN1 inhibitors and therapeutic methods using the same REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2024-06-18 US disclosed
CN-115583970-A Method for preparing alpha- (hydroxy amino) diaryl phosphine oxide from nitrone 华北理工大学 2023-01-10 CN disclosed
US-20220275519-A1 CLEANING SOLUTION AND CLEANING METHOD FUJIFILM CORPORATION (JP) 2022-09-01 US disclosed
US-20200109167-A1 SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME UNIV MICHIGAN REGENTS (US) 2020-04-09 US disclosed
EP-3601245-A1 SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME The Regents of The University of Michigan (US) 2020-02-05 EP disclosed
WO-2018183411-A1 SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2018-10-04 WO disclosed
EP-1655070-B1 OXIDATION CATALYST ASAHI KASEI CHEMICALS CORP (JP) 2015-07-15 EP disclosed
US-8133834-B2 Oxidation catalyst ASAHI KASEI CHEMICALS CORPORATION (JP) 2012-03-13 US disclosed
CN-1835800-B Oxidation catalyst ASAHI CHEMICAL CORP (JP) 2010-04-28 CN disclosed
US-20100069670-A1 Oxidation catalyst ASAHI KASEI CHEMICALS CORPORATION (JP) 2010-03-18 US disclosed
US-20060229471-A1 Oxidation catalyst ASAHI KASEI CHEMICALS CORPORATION (JP) 2006-10-12 US disclosed
CN-1835800-A Oxidation catalyst ASAHI CHEMICAL CORP (JP) 2006-09-20 CN disclosed
EP-1655070-A1 OXIDATION CATALYST Asahi Kasei Chemicals Corporation (JP) 2006-05-10 EP disclosed
EP-0621276-A1 Angiotensin II receptor blocking 2,3,6-substituted quinazolinones AMERICAN CYANAMID COMPANY (US) 1994-10-26 EP disclosed
US-5358951-A Treating hypertension, congestive heart failure AMERICAN CYANAMID COMPANY (US) 1994-10-25 US disclosed
US-5292734-A Angiotensin II receptor blocking 2,3,6 substituted quinazolinones AMERICAN CYANAMID COMPANY (US) 1994-03-08 US disclosed
US-4596874-A One step reaction of secondary amine with hydrogen peroxide in the presence of tungsten, molybdenum, vanadium, titamium catalyst THE PRESIDENT OF OSAKA UNIVERSITY (JP) 1986-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200109167-A1 SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME DCUN1D2, CLN6, CAPNS1 MAOB 1366/4885BCHE 1455/4885ACHE 1736/4885
US-20100069670-A1 Oxidation catalyst PPOX, SOD1, HAO2 MAOB 267/4885BCHE 1176/4885ACHE 1338/4885
US-12012467-B2 Small molecule DCN1 inhibitors and therapeutic methods using the same DCUN1D2, CLN6, CAPNS1 MAOB 1366/4885BCHE 1455/4885ACHE 1736/4885
US-20060229471-A1 Oxidation catalyst PPOX, SOD1, HAO2 MAOB 267/4885BCHE 1176/4885ACHE 1338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.